Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.
Journal: Clinical genitourinary cancer
Published: April 09, 2026
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo.
Journal: Research square
Published: February 27, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 26, 2026
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).
Journal: The Prostate
Published: July 15, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 29, 2025
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
Journal: European urology oncology
Published: November 04, 2024
Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer.
Journal: Human vaccines & immunotherapeutics
Published: August 29, 2024
Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 22, 2024
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: November 30, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Journal: The Lancet. Oncology
Published: March 14, 2023
Comparison of automated full-body bone metastases delineation methods and their corresponding prognostic power.
Journal: Physics in medicine and biology
Published: August 11, 2022
Last Updated: 09/26/2026